Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

计划入组 113 人 · 首次发布于 2023 年 9 月 22 日

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

计划入组 17 人 · 首次发布于 2016 年 5 月 4 日

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

计划入组 36 人 · 首次发布于 2016 年 7 月 11 日

Patidegib

C₂₉H₄₈N₂O₃S

Osteoarthritis gel

Next Gen Gel

Sol-Gel Technologies

Israel

Sol-Gel Technologies, Inc.

United States

ATHLETES GEL PTY. LTD.

Australia

Sol-Gel Completes Phase 3 Trial of Patidegib Gel 2% for Facial Basal Cell Carcinomas in Gorlin Syndrome

Sol-Gel Technologies Receives Nasdaq Extension to Regain Compliance

Sol-Gel Technologies Advances SGT-610 for Gorlin Syndrome and SGT-210 for Darier Disease